Abstract

PROSTACYCLIN (PGX) (ref. 1) is the name proposed for the metabolic product of a recently discovered enzymic transformation of the prostaglandin endoperoxides PGG2 and PGH2 (refs 2–4). Prostacyclin synthetase, the enzyme which catalyses this conversion, is particularly active in the microsomal fraction of blood vessel walls3,4 although there is evidence that it is also present in the rat stomach fundus3. The prostaglandin endoperoxides, PGG2 and PGH2, have been shown to contract arterial smooth muscle and to cause platelet aggregation5,6, whereas, in contrast, prostacyclin relaxes arterial strips and prevents platelets aggregation3. A biochemical interaction has therefore been postulated to exist between platelets and the blood vessels wall, such that endoperoxides derived from platelets are converted by the vessel wall into prostacylin, which in turn actively prevents the deposition of platelets on the vascular endothelium2,4. In general, agents which inhibit platelet aggregation, such as PGE1, increase cyclic AMP levels, whereas agents causing aggregation lower platelet cyclic AMP levels7. The ability of prostacyclin to rapidly reverse or prevent platelet aggregation suggested that its action on the platelet might, like that of PGE1, be mediated by an increase in cyclic AMP levels. This hypothesis is supported by the experiments detailed here which strongly suggest that prostacyclin generated by incubation of arachidonic acid, platelets and aortic tissue, causes a rapid and pronounced accumulation of cyclic AMP by intact platelets, as well as stimulation of adenylates cyclase in isolated platelet membranes.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.